Uwell Biopharma, Inc. (TPEX:7902)
Taiwan · Delayed Price · Currency is TWD 35.90
-0.05 (-0.14%)
At close: Sep 7, 2026
Uwell Biopharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -71.61 | -66.2 | -40.87 | -45.17 | -41.47 | -49.99 |
Depreciation & Amortization | 8.37 | 8.06 | 7.51 | 7.24 | 7.18 | 6.36 |
Stock-Based Compensation | 11.76 | 3.95 | - | - | - | - |
Other Operating Activities | -0.59 | -0.42 | 0.03 | -0.06 | - | - |
Change in Accounts Receivable | - | - | - | - | 0.02 | 0.78 |
Change in Accounts Payable | -2.99 | 3.67 | 1.53 | -1.51 | -0.1 | 1.69 |
Change in Other Net Operating Assets | -3.57 | -1.36 | -0.57 | -1.13 | -0.88 | -1.48 |
Operating Cash Flow | -58.62 | -52.31 | -32.38 | -40.63 | -35.24 | -42.64 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -6 | -2.05 | - | -2.01 | -0.62 | -1 |
Sale (Purchase) of Intangibles | -0.1 | - | - | - | - | -0.2 |
Investment in Securities | -200 | -255.5 | 58.5 | -63 | 18 | -18 |
Other Investing Activities | 0.47 | - | -1.26 | 0.21 | - | - |
Investing Cash Flow | -205.63 | -257.55 | 57.24 | -64.8 | 17.38 | -19.21 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | -5.33 | -4.55 | -4.2 | -4.19 | -4.07 |
Lease Payments | -5.31 | -5.33 | -4.55 | -4.2 | -4.19 | -4.07 |
Net Debt Issued (Repaid) | -5.31 | -5.33 | -4.55 | -4.2 | -4.19 | -4.07 |
Issuance of Common Stock | 134.42 | 332 | - | 105 | - | 80 |
Financing Cash Flow | 129.11 | 326.68 | -4.55 | 100.81 | -4.19 | 75.93 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 0.1 | 0.02 | - | 0.01 | -0 | -0.01 |
Net Cash Flow | -135.04 | 16.84 | 20.3 | -4.62 | -22.05 | 14.07 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -64.62 | -54.36 | -32.38 | -42.64 | -35.86 | -43.65 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -184634.29% | -155300.00% | -7196.22% | - | - | - |
Free Cash Flow Per Share | -0.33 | -0.35 | -0.28 | -0.48 | -0.63 | -1.85 |
Levered Free Cash Flow | -33.8 | -29.27 | -17.99 | -26.88 | -21.43 | -25.87 |
Unlevered Free Cash Flow | -33.67 | -29.18 | -17.86 | -26.74 | -21.26 | -25.61 |
Free Cash Flow After Leases | -69.93 | -59.68 | -36.94 | -46.83 | -40.05 | -47.72 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0.2 | 0.15 | 0.21 | 0.22 | 0.28 | 0.42 |
Cash Income Tax Paid | 0.39 | 0.18 | 0.01 | - | - | - |
Change in Working Capital | -6.56 | 2.31 | 0.96 | -2.64 | -0.95 | 0.99 |